{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:56:00Z","timestamp":1792662960559,"version":"4.5.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"10","funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1078907"],"award-info":[{"award-number":["1078907"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1046782"],"award-info":[{"award-number":["1046782"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1078907"],"award-info":[{"award-number":["1078907"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","award":["ECSG14014"],"award-info":[{"award-number":["ECSG14014"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In cancer, elevated activin levels promote cachectic wasting of muscle, irrespective of tumor progression. In excess, activins A and B use the myostatin signaling pathway in muscle, triggering a decrease in protein synthesis and an increase in protein degradation, which ultimately leads to atrophy. Recently, we demonstrated that local delivery of engineered activin and myostatin propeptides (natural inhibitors of these growth factors) could induce profound muscle hypertrophy in healthy mice. Additionally, the expression of these propeptides effectively attenuated localized muscle wasting in models of dystrophy and cancer cachexia. In this study, we examined whether a systemically administered recombinant propeptide could reverse activin A\u2013induced cachectic wasting in mice. Chinese hamster ovary cells stably expressing activin A were transplanted into the quadriceps of nude mice and caused an 85-fold increase in circulating activin A levels within 12 days. Elevated activin A induced a rapid reduction in body mass (\u221216%) and lean mass (\u221210%). In agreement with previous findings, we demonstrated that adeno-associated virus\u2013mediated delivery of activin propeptide to the tibialis anterior muscle blocked activin-induced wasting. In addition, despite massively elevated levels of activin A in this model, systemic delivery of the propeptide significantly reduced activin-induced changes in lean and body mass. Specifically, recombinant propeptide reversed activin-induced wasting of skeletal muscle, heart, liver, and kidneys. This is the first study to demonstrate that systemic administration of recombinant propeptide therapy effectively attenuates tumor-derived activin A insult in multiple tissues.<\/jats:p>","DOI":"10.1210\/en.2019-00257","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T16:34:42Z","timestamp":1565195682000},"page":"2417-2426","source":"Crossref","is-referenced-by-count":20,"title":["Activin A\u2013Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice"],"prefix":"10.1210","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-2958","authenticated-orcid":false,"given":"Kelly L","family":"Walton","sequence":"first","affiliation":[{"name":"Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Victoria, Australia"},{"name":"Hudson Institute of Medical Research, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Victoria, Australia"},{"name":"Hudson Institute of Medical Research, Clayton, Victoria, Australia"},{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinn","family":"Arnold","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton, Victoria, Australia"},{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Kelly","sequence":"additional","affiliation":[{"name":"Hudson Institute of Medical Research, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mylinh","family":"La","sequence":"additional","affiliation":[{"name":"National Collaborative Research Infrastructure Strategy Facility, Commonwealth Scientific and Industrial Research Organisation BioMedical Manufacturing Program, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Lu","sequence":"additional","affiliation":[{"name":"National Collaborative Research Infrastructure Strategy Facility, Commonwealth Scientific and Industrial Research Organisation BioMedical Manufacturing Program, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lovrecz","sequence":"additional","affiliation":[{"name":"National Collaborative Research Infrastructure Strategy Facility, Commonwealth Scientific and Industrial Research Organisation BioMedical Manufacturing Program, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hagg","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Physiology, Centre for Muscle Research, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D","family":"Colgan","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Qian","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Physiology, Centre for Muscle Research, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gregorevic","sequence":"additional","affiliation":[{"name":"Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia"},{"name":"Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia"},{"name":"Department of Physiology, Centre for Muscle Research, The University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, University of Washington School of Medicine, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Victoria, Australia"},{"name":"Hudson Institute of Medical Research, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"issue":"7581","key":"2019092507513706900_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/528182a","article-title":"Cachexia: the last illness","volume":"528","author":"Lok","year":"2015","journal-title":"Nature"},{"issue":"4","key":"2019092507513706900_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tem.2012.10.006","article-title":"Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem","volume":"24","author":"Tsoli","year":"2013","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2019092507513706900_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"issue":"3","key":"2019092507513706900_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab"},{"issue":"5","key":"2019092507513706900_bib5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1101\/gad.276733.115","article-title":"Mechanisms of metabolic dysfunction in cancer-associated cachexia","volume":"30","author":"Petruzzelli","year":"2016","journal-title":"Genes Dev"},{"issue":"2","key":"2019092507513706900_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"issue":"18","key":"2019092507513706900_bib7","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1158\/0008-5472.CAN-15-3152","article-title":"Differential effects of IL6 and activin A in the development of cancer-associated cachexia","volume":"76","author":"Chen","year":"2016","journal-title":"Cancer Res"},{"issue":"4","key":"2019092507513706900_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1096\/fj.13-245894","article-title":"Elevated expression of activins promotes muscle wasting and cachexia","volume":"28","author":"Chen","year":"2014","journal-title":"FASEB J"},{"issue":"11","key":"2019092507513706900_bib9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/nm1677","article-title":"Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1","volume":"13","author":"Johnen","year":"2007","journal-title":"Nat Med"},{"issue":"5572","key":"2019092507513706900_bib10","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1126\/science.1069525","article-title":"Induction of cachexia in mice by systemically administered myostatin","volume":"296","author":"Zimmers","year":"2002","journal-title":"Science"},{"key":"2019092507513706900_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-27511-6_5","article-title":"The TGF-\u03b2 signalling network in muscle development, adaptation and disease","volume":"900","author":"Chen","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"2019092507513706900_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcsm.12033","article-title":"Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients","volume":"6","author":"Lerner","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"2019092507513706900_bib13","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12209","article-title":"Circulating activin A predicts survival in cancer patients","volume":"8","author":"Loumaye","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"2019092507513706900_bib14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1161\/01.CIR.0000120704.97934.41","article-title":"Elevated levels of activin A in heart failure: potential role in myocardial remodeling","volume":"109","author":"Yndestad","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"2019092507513706900_bib15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1530\/eje.0.1480559","article-title":"Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia","volume":"148","author":"Michel","year":"2003","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2019092507513706900_bib16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1152\/japplphysiol.90719.2008","article-title":"Elevated levels of activin A in clinical and experimental pulmonary hypertension","volume":"106","author":"Yndestad","year":"2009","journal-title":"J Appl Physiol (1985)"},{"issue":"4","key":"2019092507513706900_bib17","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"issue":"26","key":"2019092507513706900_bib18","doi-asserted-by":"crossref","first-page":"E5266","DOI":"10.1073\/pnas.1620013114","article-title":"Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease","volume":"114","author":"Chen","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019092507513706900_bib19","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/mt.2014.221","article-title":"Development of novel activin-targeted therapeutics","volume":"23","author":"Chen","year":"2015","journal-title":"Mol Ther"},{"issue":"10","key":"2019092507513706900_bib20","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/en.2011-1052","article-title":"Generation of a specific activin antagonist by modification of the activin A propeptide","volume":"152","author":"Makanji","year":"2011","journal-title":"Endocrinology"},{"key":"2019092507513706900_bib21","unstructured":"RRID:AB_2801574, https:\/\/scicrunch.org\/resolver\/AB_2801574."},{"key":"2019092507513706900_bib22","unstructured":"RRID:AB_10707327, https:\/\/scicrunch.org\/resolver\/AB_10707327."},{"key":"2019092507513706900_bib23","unstructured":"RRID:AB_10167668, https:\/\/scicrunch.org\/resolver\/AB_10167668."},{"issue":"2","key":"2019092507513706900_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1677\/joe.0.1480267","article-title":"Development and application of a two-site enzyme immunoassay for the determination of \u2018total\u2019 activin-A concentrations in serum and follicular fluid","volume":"148","author":"Knight","year":"1996","journal-title":"J Endocrinol"},{"issue":"4","key":"2019092507513706900_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2004.07.016","article-title":"Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6 [published correction appears in Mol Ther. 2009;17(8):1482]","volume":"10","author":"Blankinship","year":"2004","journal-title":"Mol Ther"},{"issue":"23","key":"2019092507513706900_bib26","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1101\/gad.11.23.3157","article-title":"Dual role of the Smad4\/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes","volume":"11","author":"Liu","year":"1997","journal-title":"Genes Dev"},{"key":"2019092507513706900_bib27","unstructured":"RRID:AB_2099233, https:\/\/scicrunch.org\/resolver\/AB_2099233."},{"issue":"4","key":"2019092507513706900_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.15252\/emmm.201607231","article-title":"Supraphysiological levels of GDF11 induce striated muscle atrophy","volume":"9","author":"Hammers","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2019092507513706900_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"issue":"4","key":"2019092507513706900_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"2019092507513706900_bib31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for Becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol Ther"},{"issue":"3","key":"2019092507513706900_bib32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"issue":"4","key":"2019092507513706900_bib33","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/hep.1840200413","article-title":"Induction of apoptosis in the murine liver with recombinant human activin A","volume":"20","author":"Hully","year":"1994","journal-title":"Hepatology"},{"key":"2019092507513706900_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front Pharmacol"},{"issue":"47","key":"2019092507513706900_bib35","doi-asserted-by":"crossref","first-page":"36645","DOI":"10.1074\/jbc.M110.177865","article-title":"Activin A binds to perlecan through its pro-region that has heparin\/heparan sulfate binding activity","volume":"285","author":"Li","year":"2010","journal-title":"J Biol Chem"},{"issue":"12","key":"2019092507513706900_bib36","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.1501303112","article-title":"Structure of bone morphogenetic protein 9 procomplex","volume":"112","author":"Mi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7351","key":"2019092507513706900_bib37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature10152","article-title":"Latent TGF-\u03b2 structure and activation","volume":"474","author":"Shi","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2019092507513706900_bib38","doi-asserted-by":"crossref","first-page":"12052","DOI":"10.1038\/ncomms12052","article-title":"Structure and activation of pro-activin A","volume":"7","author":"Wang","year":"2016","journal-title":"Nat Commun"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/en.2019-00257\/28953511\/en.2019-00257.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/160\/10\/2417\/30052872\/en.2019-00257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T08:26:57Z","timestamp":1664094417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/160\/10\/2417\/5535647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2019-00257","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,7,19]]}}}